Rare RET fusion and MET amplification double mutations in a case of lung cancer with brain metastasis

doi:10.3760/cma.j.issn.1007-1245.2023.04.031

International Medicine and Health Guidance News ›› 2023, Vol. 29 ›› Issue (4): 574-576.DOI: 10.3760/cma.j.issn.1007-1245.2023.04.031

• Case Report • Previous Articles Next Articles

Rare RET fusion and MET amplification double mutations in a case of lung cancer with brain metastasis

Xing Shujing¹, Hua Lanlan²

¹Department of Clinical Oncology, Weihai Central Hospital, Weihai 264400, China; ²Department of Doppler Ultrasonics, Weihai Central Hospital, Weihai 264400, China

Received:2022-09-20 Online:2023-03-15 Published:2023-03-06
Contact: Xing Shujing, Email: shujingxing@163.com

罕见RET融合及MET扩增双突变的肺癌脑转移1例

邢淑静¹ 滑兰兰²

¹威海市中心医院肿瘤内科，威海　264400；²威海市中心医院超声科，威海　264400

通讯作者: 邢淑静，Email：shujingxing@163.com

Abstract

Abstract:

This was a rare case of brain metastases from lung cancer with RET fusion and MET amplification double mutations. After double target treatment with crizotinib and cabotinib combined with whole brain radiotherapy, clinical remission had been achieved.

Key words:

Lung cancer, Brain metastases, RET fusion, MET amplification

摘要：

本例患者为肺癌脑转移，合并RET融合及MET扩增双突变，临床罕见。经过克唑替尼联合卡博替尼双靶治疗和全脑放疗，获得临床缓解。

关键词:

肺癌, 脑转移, RET融合, MET扩增

Xing Shujing, Hua Lanlan.

Rare RET fusion and MET amplification double mutations in a case of lung cancer with brain metastasis [J]. International Medicine and Health Guidance News, 2023, 29(4): 574-576.

邢淑静滑兰兰.

罕见RET融合及MET扩增双突变的肺癌脑转移1例 [J]. 国际医药卫生导报, 2023, 29(4): 574-576.

References

[1] 郏博,吕超,常建华,等. 非小细胞肺癌非常见突变靶向治疗研究进展[J]. 中华医学杂志,2022,102(13):969-976. DOI:10.3760/cma.j.cn112137-20211008-02215.
[2] Takeuchi K. Discovery stories of RET fusions in lung cancer: a mini-review [J]. Front Physiol, 2019, 10: 216. DOI: 10.3389/fphys.2019.00216.
[3] 马千里,张瑾,鲍彤,等. RET融合肺癌的特征及诊疗进展[J]. 中华胸心血管外科杂志,2022,38(5):305-309. DOI:10.3760/cma.j.cn112434-20210219-00062.
[4] Kato S, Subbiah V, Marchlik E, et al. RET aberrations in diverse cancers: next-generation sequencing of 4,871 patients [J]. Clin Cancer Res, 2017, 23(8):1988-1997. DOI: 10.1158/1078-0432.CCR-16-1679.
[5] Lee J, Ku BM, Shim JH, et al. Characteristics and outcomes of RET-rearranged Korean non-small cell lung cancer patients in real-world practice[J]. Jpn J Clin Oncol, 2020, 50(5): 594-601. DOI: 10.1093/jjco/hyaa019.
[6] Frampton GM, Ali SM, Rosenzweig M, et al. Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors [J].Cancer Discov, 2015, 5(8): 850-859. DOI: 10.1158/2159-8290.CD-15-0285.
[7] Cappuzzo F, Marchetti A, Skokan M, et al. Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients[J]. J Clin Oncol, 2009, 27(10): 1667-1674. DOI: 10.1200/JCO.2008.19.1635.
[8] Baldacci S, Kherrouche Z, Cockenpot V. MET amplification increases the metastatic spread of EGFR-mutated NSCLC [J]. Lung Cancer, 2018, 125:57-67. DOI: 10.1016/j.lungcan.2018.09.008.
[9] 吴丹,李静,姚梅宏,等.非小细胞肺癌表皮生长因子受体、间变性淋巴瘤激酶、ROS1基因突变及突变共存的临床病理学意义[J].中华病理学杂志,2021,50(3): 251-253. DOI: 10.3760/cma.j.cn112151-20200617-00482.

Rare RET fusion and MET amplification double mutations in a case of lung cancer with brain metastasis

罕见RET融合及MET扩增双突变的肺癌脑转移1例

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 0

Recommended Articles

Metrics